Collectively, the AAV-CYP46A1 delivery to animal models of AD, HD, Sca3, and ALS enabled major insights into the role of the CYP46A1 defect in neurodegenerative diseases and CYP46A1 mechanisms of therapeutic action. This evidence concerns the gene CYP46A1 and amyotrophic lateral sclerosis.